ACGME-I accredited General Surgery Residency Program, Tawam Hospital, Al Ain, UAE
Case Series
177Lu-PSMA Therapy an Alternative Therapy for Metastatic Castrate Resistant Prostate Cancer with Suboptimal Response: Are we ready for it
Author(s): Sharifa Al Sheebani, Ajda Altinoz*, Lutfi A Kurban, Saadia Ibrahim, Gehad Nassar, Hussam Sadaqa, Jawaher A Ansari, Sulaman R Magdub, Sahar Mohsin, Iram Syed, Aftab Bhatti and Rizwan Syed
Introduction: Lutetium-177-PSMA-617 (177Lu-PSMA) is used as the last treatment option in metastatic castrate resistant prostate cancer (mCRPC). We present two cases of mCRPC with bone involvement to see the response of 177Lu-PSMA as an alternative treatment option.
Case presentations: We present two cases, diagnosed as mCRPC with bone involvement, having suboptimal labelling and binding of the tracer and its effect on bone marrow. The two patients had 2-4 cycles of 177Lu-PSMA with progressive disease despite chemotherapy and novel androgen therapy. The response of treatment was determined based on changes in radiological findings, biochemical and post-therapeutic scan. The last post therapy SPECT CT 99mTc-PSMA scans in both patients showed diffuse homogenous tracer distribution in the bone marrow with no sugge.. View More»
